N-hydroxy-demethylcantharimide | 88179-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-hydroxy-demethylcantharimide
• 英文别名: 2-hydroxy-hexahydro-4,7-epioxido-isoindole-1,3-dione；4,7-Epoxy-1H-isoindole-1,3(2H)-dione, hexahydro-2-hydroxy-；2-hydroxy-3a,4,5,6,7,7a-hexahydro-4,7-epoxyisoindole-1,3-dione
• CAS: 88179-68-4
• 化学式: C₈H₉NO₄
• 分子量: 183.164
• InChiKey: SHKHCVKMZYADDO-UHFFFAOYSA-N

物化性质

• 熔点：
  195-197 °C
• 沸点：
  376.6±52.0 °C(Predicted)
• 密度：
  1.642±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-hydroxy-demethylcantharimide 、 三(对甲基苯基)二溴化锑 在 Et₃N 作用下， 以 四氢呋喃 为溶剂， 以60.2%的产率得到
  参考文献：
  名称：

  Synthesis, crystal structures and in vitro antitumor activities of some arylantimony derivatives of analogues of demethylcantharimide

  摘要：

  A series of novel aylantimony derivatives of analogues of demethylcantharimide with the formulae ArnSbL(5-n) and ArnSbL'((5-n))(LH = N-hydroxy-demethyldehydrogencantharimide, L'H = N-hydroxy-demethyleantharimide, n = 3, 4; Ar=C6H5, 4CH(3)C(6)H(4), 3-CH3C6H4, 2-CH3C6H4, 4-ClC6H4, 4-FC6H4) were synthesized and characterized by elemental analysis, IR, 1 H NMR and mass spectroscopy. The crystal structures of (C6H5)(4)SbL, (4-CH3C6H4)(3)SbL2 and (3-CHC6H4)(3)SbL'(2) were determined by X-ray diffraction. The in vitro antitumor activities of all compounds against six cancer cells are reported. (C) 2004 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2004.02.015
• 作为产物：
  描述：

  N-hydroxy-3,6-epoxy-1,2,3,6-tetrahydrophthalimide 以89%的产率得到
  参考文献：
  名称：

  Cheng Shiquan, Wulijimuren, Wang Peizhu, Cao Jinjiang, Li Fengying, Haxue shiji (Chem. Reagents.), 15 (1993) N 1, S 1-4

  摘要：

  DOI：

文献信息

• Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
  申请人：Levin I. Jeremy

  公开号：US20060211730A1

  公开（公告）日：2006-09-21

  This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compounds.

  这项发明提供了具有结构的Formula I的化合物，这些化合物在治疗由TNF-α介导的疾病或紊乱方面非常有用，如关节炎（类风湿关节炎（RA），幼年RA，银屑病性关节炎，骨关节炎等），肿瘤转移，组织溃疡，异常伤口愈合，牙周病，骨病，糖尿病（胰岛素抵抗）和HIV感染，强直性脊柱炎，银屑病，败血症，多发性硬化，克罗恩病，退行性软骨丢失，哮喘，特发性肺纤维化，血管炎，系统性红斑狼疮，肠易激综合征，急性冠状动脉综合征，丙型肝炎，虚弱，慢性阻塞性肺病，中风或2型糖尿病的缓解症状。该发明还提供了使用这些化合物的方法。
• Cheng Shiquan, Wulijimuren, Wang Peizhu, Cao Jinjiang, Li Fengying, Haxue shiji (Chem. Reagents.), 15 (1993) N 1, S 1-4
  作者：Cheng Shiquan, Wulijimuren, Wang Peizhu, Cao Jinjiang, Li Fengying

  DOI：——

  日期：——
• US7595327B2
  申请人：——

  公开号：US7595327B2

  公开（公告）日：2009-09-29
• US9244345B1
  申请人：——

  公开号：US9244345B1

  公开（公告）日：2016-01-26
• Synthesis, crystal structures and in vitro antitumor activities of some arylantimony derivatives of analogues of demethylcantharimide
  作者：Guo-Cang Wang、Jian Xiao、Lin Yu、Jin-Shan Li、Jing-Rong Cui、Rui-Qing Wang、Fu-Xiang Ran

  DOI：10.1016/j.jorganchem.2004.02.015

  日期：2004.5

  A series of novel aylantimony derivatives of analogues of demethylcantharimide with the formulae ArnSbL(5-n) and ArnSbL'((5-n))(LH = N-hydroxy-demethyldehydrogencantharimide, L'H = N-hydroxy-demethyleantharimide, n = 3, 4; Ar=C6H5, 4CH(3)C(6)H(4), 3-CH3C6H4, 2-CH3C6H4, 4-ClC6H4, 4-FC6H4) were synthesized and characterized by elemental analysis, IR, 1 H NMR and mass spectroscopy. The crystal structures of (C6H5)(4)SbL, (4-CH3C6H4)(3)SbL2 and (3-CHC6H4)(3)SbL'(2) were determined by X-ray diffraction. The in vitro antitumor activities of all compounds against six cancer cells are reported. (C) 2004 Elsevier B.V. All rights reserved.